Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006368 · ClinicalTrials.gov registry record · Phase 1
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00006368 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00006368, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of yttrium Y 90 SMT 487 in treating patients who have refractory or recurrent cancer.
Interventions
- RADIATION yttrium Y 90-edotreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1998-01 |
| Est. Completion | 2003-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006368
The ClinicalTrials.gov registry entry for NCT00006368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which yttrium Y 90-edotreotide is the first listed.
NCT00006368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006368 about?
NCT00006368 is a clinical study titled "Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer". RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of yttrium Y 90 SMT 487 in treating patients who have refractory or recurrent cancer.
What is the current status of trial NCT00006368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 1998-01. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00006368?
The interventions under investigation include: yttrium Y 90-edotreotide (RADIATION).
Who is sponsoring clinical trial NCT00006368?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.